Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review

The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma i...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2021/04/01, Vol.60(7), pp.1067-1071
Main Authors: Yoshimatsu, Yuki, Ebi, Noriyuki, Ooi, Ryunosuke, Sueyasu, Takuto, Nishizawa, Saori, Munechika, Miyuki, Yoshimine, Kohei, Ko, Yuki, Ide, Hiromi, Tsuruno, Kosuke, Tobino, Kazunori
Format: Article
Language:English
Subjects:
Acrylamides
adenosquamous
Aniline Compounds
Antineoplastic Agents - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - genetics
Case Report
Chemotherapy
EGFR
Epidermal growth factor
epidermal growth factor receptor
Epidermal growth factor receptors
ErbB Receptors - genetics
Humans
Internal medicine
Literature reviews
Lung
Lung carcinoma
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Mutants
Mutation
Protein Kinase Inhibitors - therapeutic use
Protein-tyrosine kinase receptors
rechallenge
Squamous cell carcinoma
TKI
tyrosine kinase inhibitor
Ultraviolet radiation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.5463-20